Drug Development for Rare Cancers in Children

Lia Gore, MD

  H&O  How is a rare cancer defined? LG  Approximately 1.6 million cases of cancer are diag­nosed each year in the United States. The US Food […]

Locoregional Therapy for Liver Metastases in Colorectal Cancer

Andrew S. Kennedy, MD

  H&O  How often does colorectal cancer (CRC) metastasize to the liver? AK  The exact frequency has been controversial for a long time. Current data suggest […]

Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease

Steven S. Yu, MD, Tanya B. Dorff, MD, Leslie K. Ballas, MD, Sarmad Sadeghi, MD, PhD, Eila C. Skinner, MD, and David I. Quinn, MBBS (Hons), PhD, FRACP, FACP

  Abstract: Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this […]

Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer

David J. Einstein, MD, and David F. McDermott, MD

  Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]

Use of Genetic Markers in Multiple Myeloma

Rafael Fonseca, MD

  H&O  In what ways is multiple myeloma a genetically heterogeneous disease? RF  In an editorial written several years ago, I referred to this disease as […]

Programmed Death Ligand 1 Testing: Is There One Best Test?

Fred R. Hirsch, MD, PhD

  H&O  Is programmed death ligand 1 (PD-L1) testing always done before prescribing a programmed death 1 (PD-1)/PD-L1 inhibitor in patients with non–small cell lung cancer […]

Counterpoints: Should Treatment for CML Continue Indefinitely?

Nicholas J. Short, MD, Elias Jabbour, MD, Gabriel Etienne, MD, PhD, and François-Xavier Mahon, MD, PhD

Since the advent of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has been transformed from a disease that was usually fatal into one in which […]

The BALAD-2 and GALAD Biomarker Models for Hepatocellular Carcinoma

Philip J. Johnson, MD

  H&O  Do biomarkers currently have a role in hepatocellular carcinoma? PJ  The role of biomarkers in hepatocellular carcinoma (HCC) is controversial. For example, the best-known […]

Letter From the Editor: In Memory of Robert L. Comis, MD

Brad S. Kahl, MD

I recently attended the Spring ECOG-ACRIN Cancer Research Group meeting. One evening I was able to spend some time at the bar with Group co-chair Bob Comis, […]

Back to Archive